Trial Profile
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2017
Price :
$35
*
At a glance
- Drugs Alvelestat (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms BREEZE
- Sponsors AstraZeneca
- 18 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.